Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Calithera Biosciences, Inc. (NASDAQ: CALA).

Full DD Report for CALA

You must become a subscriber to view this report.


Recent News from (NASDAQ: CALA)

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2018 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) Q3 2018 Earnings Conference Call November 07, 2018, 17:00 ET Executives Jennifer McNealey - VP, IR & Strategy Susan Molineaux - Co-Founder, CEO, President & Director Keith Orford - SVP, Clinical Development Stephanie Wong - SVP, Financ...
Source: SeekingAlpha
Date: November, 07 2018 20:49
Calithera Biosciences reports Q3 results
Calithera Biosciences (NASDAQ: CALA ): Q3 GAAP EPS of -$0.52. More news on: Calithera Biosciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: November, 07 2018 16:37
Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatmen...
Source: GlobeNewswire
Date: November, 07 2018 16:05
Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatmen...
Source: GlobeNewswire
Date: October, 31 2018 08:00
Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced its participation at two upcoming healthcare conferences in September. ...
Source: GlobeNewswire
Date: August, 29 2018 07:05
Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences - Renewed Outlook, Key Drivers of Growth
NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI), Organovo Holdings, Inc. (NASDAQ:ONVO), Calit...
Source: GlobeNewswire
Date: August, 14 2018 20:15
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2018 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) Q2 2018 Earnings Conference Call August 07, 2018, 05:00 PM ET Executives Jennifer McNealey - VP, IR & Strategy Susan Molineaux - Co-Founder, President & CEO Stephanie Wong - Senior VP, Finance and Secretary Keith Orford - SVP, Clinical...
Source: SeekingAlpha
Date: August, 07 2018 22:55
Calithera Biosciences beats by $0.23, beats on revenue
Calithera Biosciences (NASDAQ: CALA ): Q2 EPS of -$0.09 beats by $0.23 . More news on: Calithera Biosciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 16:30
Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights
- Two Novel Programs Entering Clinical Development -Calithera to Host Conference Call Today at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutica...
Source: GlobeNewswire
Date: August, 07 2018 16:08
Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment...
Source: GlobeNewswire
Date: August, 01 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-184.404.264.494.21289,351
2018-12-174.604.354.62644.34193,511
2018-12-144.754.604.804.595144,461
2018-12-134.914.794.954.73120,804
2018-12-124.894.885.034.8497152,400

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1820,49382,18224.9361Cover
2018-12-1720,90969,31530.1652Cover
2018-12-1414,22938,25937.1912Short
2018-12-1313,77334,10240.3877Short
2018-12-1211,19630,06937.2344Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CALA.


About Calithera Biosciences, Inc. (NASDAQ: CALA)

Logo for Calithera Biosciences, Inc. (NASDAQ: CALA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CALA)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 10 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: May, 01 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 10 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 08 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 08 2018
      Amendment to a previously filed Form 3
      Filing Type: 3/AFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: CALA)

      Daily Technical Chart for (NASDAQ: CALA)


      Stay tuned for daily updates and more on (NASDAQ: CALA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CALA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CALA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CALA and does not buy, sell, or trade any shares of CALA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/